Low-intensity ultrasound therapy (LIUST) has been described as a plausible treatment for chronic rhinosinusitis (CRS). Aims: To evaluate the short-term effects of continuous 1MHz LIUST on nasal obstruction in subjects with CRS. Material and Method: A cohort placebo-controlled study comprising 26 CRS adults (10 men, 16 women), sequentially allocated into two groups: control-placebo (CP, n= 12) and treated with LIUST (US, n= 14). The treatment consisted of: ISATA = continuous 1MHz, 1W.cm-2 for four minutes in the maxillary sinuses and nasal septum. The equipment was switched off in the CP group. The degree of obstruction was assessed by the total volume of secretion expelled (VSEx) after nasal instillation of 5 mL saline solution (NaCl-0.9%) followed by nasal lavage. The volume of expired air (VEA) was assessed with a Glatzel mirror. Results: The data showed an increase (p<0.01) in VSEx and VEA after ultrasound therapy, suggesting a 64% improvement of nasal obstruction compared with the CP group. Conclusions: Continuous LIUST reduced nasal obstruction and congestionç it may be used effectively in the respiratory therapy of CRS patients.

Background: Liver is the third most common site of breast cancer metastases. Resection of breast cancer liver metastases (BCLM) is a treatment option which remains controversial. Recently there is increased interest in offering liver resection for BCLM. However, the evidence remains low quality.This study aims to review the current practice of UK Hepato-pancreato-biliary (HPB) units regarding hepatic resections for BCLM as part of setting up a protocol for a multicentre randomised control trial. Materials and Methods: HPB units across UK were asked to take part in an online survey comprised of 11 questions. The questionnaire covered three years of clinical practice up to 2015. The survey was voluntary and anonymous. Results: 26 HPB units responded including 5, 19 and 2 from Scotland, England and Northern Ireland respectively. Majority of the HPB units performed more than 50 liver resections and up to 30 radiofrequency ablations (RFA) for all types of liver cancers per year. 75% of the HPB units performed less than 5 liver resections or RFA procedures for BCLM over the three years period.Out of 26 HPB units, 23 showed interest to participate in the RCT. Conclusion: Liver resections for BCLM are infrequently performed in the UK. There is an inclusive interest of participation in a future RCT.